These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 28811384

  • 1. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY, Tsai YC, Yeh HL, Suau F, Jiang KC, Shao AN, Huang J, Liu YN.
    Sci Signal; 2017 Aug 15; 10(492):. PubMed ID: 28811384
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC, Chen WY, Abou-Kheir W, Zeng T, Yin JJ, Bahmad H, Lee YC, Liu YN.
    Biochim Biophys Acta Mol Basis Dis; 2018 May 15; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.
    Huang PA, Price DK, Figg WD.
    Cancer Biol Ther; 2018 May 15; 19(10):869-870. PubMed ID: 29757697
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
    Haller AC, Tan W, Payne-Ondracek R, Underwood W, Tian L, Morrison C, Li F.
    Prostate; 2014 May 15; 74(5):509-19. PubMed ID: 24375440
    [Abstract] [Full Text] [Related]

  • 12. ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.
    Fararjeh AS, Liu YN.
    Int J Mol Sci; 2019 Jun 08; 20(11):. PubMed ID: 31181727
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI.
    Lee MJ, Heo SC, Shin SH, Kwon YW, Do EK, Suh DS, Yoon MS, Kim JH.
    Int J Biochem Cell Biol; 2013 Aug 08; 45(8):1869-77. PubMed ID: 23735324
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The transcription factor SPDEF suppresses prostate tumor metastasis.
    Steffan JJ, Koul S, Meacham RB, Koul HK.
    J Biol Chem; 2012 Aug 24; 287(35):29968-78. PubMed ID: 22761428
    [Abstract] [Full Text] [Related]

  • 17. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Øyan AM, Kalland K.
    BMC Cancer; 2016 Jul 04; 16():377. PubMed ID: 27378372
    [Abstract] [Full Text] [Related]

  • 18. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY, Jan YJ, Kuo LK, Wang BJ, Huo C, Jiang SS, Chen SC, Kuo YY, Chang CR, Chuu CP.
    Cancer Sci; 2018 Nov 04; 109(11):3564-3574. PubMed ID: 30142696
    [Abstract] [Full Text] [Related]

  • 19. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK, Chen WY, Tsai HY, Chen HY, Yin JJ, Chen CL, Tsai YC, Liu YN.
    Prostate Cancer Prostatic Dis; 2017 Jun 04; 20(2):172-178. PubMed ID: 28220803
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.